Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Wed, 19.02.2025       https://research-hub.de/companies/123fahrschule SE

123fahrschule SE (123fs) has successfully completed the issuance of a convertible bond with a nominal value of up to EUR 3.4m, divided into 1,027,723 units at a nominal value of EUR 3.30 each. The bond carries an annual interest rate of 7.5% and a duration of 5 years. The offer was fully subscribed by existing shareholders and institutional investors, securing the capital raising to finance the company’s growth plans. For FY25, 123fs projects revenues of EUR 28-30m and an EBITDA of EUR 1.5-2.5m, with simulators expected to drive growth. Legislative changes and an expanding branch network bolster the outlook. mwb research’s analysts maintain their EUR 6.20 target price and BUY rating. The full update can be downloaded under https://www.research-hub.de/companies/research/123fahrschule%20SE
Wed, 19.02.2025       https://research-hub.de/companies/MS Industrie AG

During mwb research’s roundtable yesterday, Dr. Andreas Aufschnaiter, CEO of MS Industrie, outlined the company’s transformation and strategic focus. In mid-2024, MS Industrie sold 51% of MS Ultraschall to concentrate on its core business, MS XTEC, which primarily supplies mechanical parts for heavy-duty trucks. Dr. Aufschnaiter also discussed the challenges in the truck market, noting that the 17.5% yoy decline in the order backlog in 2024 was driven by market uncertainty, causing truck manufacturers to reduce their inventories. Despite this, he highlighted early signs of recovery, with the order backlog increasing 8.9% yoy in January 2025. The potential for catch-up effects and higher demand is not yet reflected in mwb research’s conservative estimates. mwb research’s analysts maintain their BUY rating with an unchanged PT of EUR 2.40, offering a 64% upside, as the analysts look for further signs of a sustainable recovery in demand. You can find the roundtable recording here: https://research-hub.de/events/video/2025-02-18-13-30/MSAG-GR. The full update can be downloaded under https://research-hub.de/companies/ms-industrie-ag
Tue, 18.02.2025       https://research-hub.de/companies/Elmos Semiconductor SE

Elmos delivered a resilient Q4, with sales of EUR 146m (-6.9% qoq) and a strong operating EBIT margin of 24.8% (-0.7pp qoq), showcasing its ability to navigate ongoing inventory overhang and subdued demand. This brought FY24 revenue to EUR 581.1m (+1.1% yoy) and a stable EBIT margin of 25.1% (-1pp yoy), outperforming many peers facing sales declines. Operating cash flow for FY24 came in at EUR 16.3m (2023: EUR 102.6m), significantly impacted by a tax payment of EUR 100m in Q4. The outlook for 2025 remains cautious yet in line, with flat sales guidance of EUR 580m ±30m and an EBIT margin of 23% ± 3pp, though adjusted FCF is set to improve significantly to +7% ±2pp of sales (2024: 0.9%) due to strategic initiatives. With a leading market position in automotive applications, disciplined execution, and record design wins, Elmos remains well-positioned for long-term structural growth. mwb research’s analysts reiterate their BUY rating with a PT of EUR 98.00. The full update can be downloaded under https://research-hub.de/companies/Elmos%20Semiconductor%20SE
Tue, 18.02.2025       https://research-hub.de/companies/Formycon AG

Formycon has lowered its expectations for the U.S. market, adjusting its commercialization outlook amid steep pricing pressures and fierce competition. The company announced significant impairments for FYB202 and FYB201, reflecting reduced revenue projections in the highly competitive U.S. biosimilar space. With multiple Stelara biosimilars set to launch, Formycon now anticipates lower peak sales for FYB202, while FYB201 faces potential commercialization delays as Sandoz reconsiders its approach. On the positive side, the termination of the Phase III "Lotus" trial (FYB206) provides substantial cost savings, helping to offset some financial strain. After model revision, mwb research now assign Formycon a PT of EUR 62.00 and resume their BUY rating, implying strong recovery potential following the sharp decline. More updates are expected in March 2025. The full update can be downloaded under https://www.research-hub.de/companies/Formycon%20AG
Tue, 18.02.2025       ad pepper media International N.V.

Company Name: ad pepper media International N.V. ISIN: NL0000238145   Reason for the research: Update Recommendation: Buy from: 18.02.2025 Target price: 2,90 Euro Target price on sight of: 12 Monate Last rating change: 20.07.2020: Hochstufung von Hinzufügen auf Kaufen Analyst: Dr. Karsten von Blumenthal First Berlin Equity  [ … ]
Mon, 17.02.2025       https://research-hub.de/companies/Formycon AG

Formycon has delivered a highly negative update on its commercialization pipeline, causing a sharp market reaction. The company announced potential major financial impairments for FYB202 and FYB201, driven by higher-than-expected price discounts in the U.S. biosimilar market. Additionally, FYB201’s commercialization is now uncertain, as discussions with Sandoz AG continue, and a temporary pause in U.S. sales is under consideration. Meanwhile, FYB202 faces a significant impairment charge due to pricing pressures, further straining revenue expectations. Following a sharp decline in its stock price, the company has scheduled an analyst call for later today. Mwb research put the rating under review and suspended the price target until they have reassessed their financial model in light of these developments. The full update can be downloaded under https://www.research-hub.de/companies/Formycon%20AG
Mon, 17.02.2025       https://research-hub.de/companies/ZEAL Network SE

ZEAL’s FY24 report on March 26, 2025, will set the stage for its FY25 outlook, with momentum firmly in place. Despite jackpot-fueled highs in 2024, ZEAL isn’t a one-hit wonder—its structurally expanding customer base, digital lottery shift, and diversified revenue streams position it for growth in 2025 (mwb est. ~+7% yoy), even in a normalized jackpot cycle. A unique scalable and asset-light model drives strong margins (mwb est. ~30% EBITDA) and robust cash flow, propelling shareholder value through dividends, and buybacks. In a high high-barrier-to-entry market ZEAL possess a competitive moat and face no real threats. ZEAL remains a resilient play and a compelling hedge in light of ongoing economic uncertainty in Germany. mwb research reiterate their BUY recommendation with an unchanged price target of EUR 60.00. The full update can be downloaded under https://www.research-hub.de/companies/ZEAL%20Network%20SE
Mon, 17.02.2025       https://research-hub.de/companies/Hensoldt AG

NATO is pushing for higher defense spending, with a new target of at least 3% of GDP according to NATO Secretary-General Mark Rutte —up 50% from current levels. In 2024, EU and Canadian defense investments surged to EUR 462bn, with European NATO members contributing EUR 326bn. Hensoldt has benefited from this trend, securing around 0.7% of European NATO defense spending. However, long-term growth prospects beyond 2030 are uncertain due to reliance on existing platforms and increasing competition. Despite involvement in key programs, Hensoldt lacks transformative growth drivers, with recurring revenues offering only limited support according to the analysts. Given the strong recent stock performance and modest revenue adjustments post-2026, the analysts raise their PT to EUR 45.00 (prev. EUR 43.00) but downgrade Hensoldt to HOLD (from BUY). The full update can be downloaded under https://www.research-hub.de/companies/Hensoldt%20AG.
Mon, 17.02.2025       https://research-hub.de/companies/Rheinmetall AG

With NATO raising defense spending targets, Rheinmetall stands to benefit significantly according to mwb research. At the Munich Security Conference, NATO Secretary-General Mark Rutte called for increased defense spending “north of 3%”. European NATO members already increased defense budgets by nearly 20% in 2024, reaching EUR 326bn. Rheinmetall secured ~3% of this spending and is well-positioned for further growth. Rheinmetall’s focus on tanks, ammunition, and drones aligns with NATO's priorities, ensuring long-term demand. Despite short-term volatility, Rheinmetall remains the key player in European defense. Given the improved revenue outlook, the analysts raise their price target to EUR 1,025.00 (prev. EUR 800.00) and reiterate their BUY rating. The full update can be downloaded under https://www.research-hub.de/companies/Rheinmetall%20AG
Mon, 17.02.2025       Desert Gold Ventures Inc.

Company Name: Desert Gold Ventures Inc. ISIN: CA25039N4084   Reason for the research: Research Comment Recommendation: Buy Target price: 0.425 CAD Target price on sight of: 31.12.2025 Last rating change: Analyst: Matthias Greiffenberger, Marcel Goldmann Under the new mining code, the government has increased its stake in new mi [ … ]

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Thursday, 17.07.2025, Calendar Week 29, 198th day of the year, 167 days remaining until EoY.